DHR vs ILMN vs JANL Stock Comparison

Danaher, Illumina and Janel Prices as of Oct 28, 2026 Peers: Industry group
DHR Danaher Corp /De/
$234.09 +2.9% 1M +7.9% 1Y
Market cap
$166.02B
P/E
41.5x
Revenue (TTM)
$25.11B
Div. yield
–
Life Sciences Tools Healthcare
3 wins
ILMN Illumina, Inc.
$288.79 +6.2% 1M +195.3% 1Y
Market cap
$43.30B
P/E
52.5x
Revenue (TTM)
$4.49B
Div. yield
–
Life Sciences Tools Healthcare
3 wins
JANL Janel Corp
$48.00 0.0% 1M +33.3% 1Y
Market cap
$56.94M
P/E
10.4x
Revenue (TTM)
$237.21M
Div. yield
–
Logistics Industrials
5 wins

Head to Head

11 decided of 12

Janel leads on 5 of the 12 questions below (Janel 5, Danaher 3, Illumina 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDHRILMNJANLLeader
Larger companyMarket capitalisation $166.02B $43.30B $56.94M DHR
Cheaper on earningsLower P/E, profitable companies only 41.5x 52.5x 10.4x JANL
Cheaper on forward earningsLower price / next fiscal year consensus EPS 25.7x 57.9x — DHR
Faster revenue growthRevenue growth, trailing twelve months +4.6% +4.9% +16.0% JANL
More profitableNet margin, trailing twelve months 15.9% 18.4% 2.3% ILMN
Better return on capitalReturn on invested capital 5.7% 15.1% 10.2% ILMN
Less leveragedLower net debt / EBITDA 2.9x 0.7x -0.6x JANL
Higher dividend yieldTrailing dividend yield 0.00% 0.00% — –
Better 1-year returnPrice return, last 12 months +7.9% +195.3% +33.3% ILMN
Better 5-year returnAnnualised price return, 5 years -5.6%/yr -6.5%/yr +16.9%/yr JANL
Less volatileAnnualised volatility, 1 year 30.6% 50.4% 77.9% DHR
Higher overall scoreMean of the five percentile scores vs peers 60/100 65/100 74/100 JANL

Percentile Scorecard

DHRILMNJANL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDHRILMNJANL
Valuation 69 #72 of 227 50 #115 of 227 97 #5 of 136
Growth 22 #172 of 219 46 #119 of 219 91 #12 of 122
Profitability 88 #26 of 205 97 #8 of 205 66 #40 of 116
Financial Health 46 #129 of 237 51 #116 of 237 41 #85 of 143
Shareholder Returns 75 #34 of 135 83 #24 of 135 –
Overall 60 65 74
  • DHR ranked among 247 companies in Medical Devices and Diagnostics
  • ILMN ranked among 247 companies in Medical Devices and Diagnostics
  • JANL ranked among 150 companies in Transportation

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDHRILMNJANLSPY
1 month +2.9%+6.2%0.0% +0.9%
3 months +19.1%+48.2%-17.2% +5.9%
6 months +30.9%+139.9%-7.2% +8.5%
Year to date +2.3%+120.2%+20.0% +13.3%
1 year +7.9%+195.3%+33.3% +12.4%
3 years +24.6%+171.8%+88.2% +88.1%
3 years, per year +7.6%+39.6%+23.5% +23.5%
5 years -24.9%-28.5%+118.2% +68.2%
5 years, per year -5.6%-6.5%+16.9% +11.0%
10 years +199.4%+114.2%+710.8% +263.4%
10 years, per year +11.6%+7.9%+23.3% +13.8%

Risk

MeasureDHRILMNJANLSPY
Volatility, 1Y 30.6%50.4%77.9% 12.7%
Downside volatility, 1Y 31.7%39.0%145.2% 12.7%
Beta vs S&P 500, 1Y 0.450.830.22 1.00
Return / volatility, 1Y 0.263.880.43 0.98
Max drawdown, 5Y -50.8%-82.9%-62.3% -25.4%
From 52-week high -3.3%-1.7%-17.2% -0.9%
52-week high $242.05$293.69$58.00 $779.14
52-week low $161.91$95.03$30.50 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDHRILMNJANL
P/E now vs peer median 41.2xmedian 28.8x 52.9xmedian 28.8x 10.4xmedian 16.1x
P/S now vs peer median 6.6xmedian 3.0x 9.7xmedian 3.0x 0.2xmedian 0.9x
EV/EBITDA now vs peer median 24.4xmedian 17.4x 38.5xmedian 17.4x 4.2xmedian 8.6x
P/FCF now vs peer median 30.1xmedian 25.7x 46.8xmedian 25.7x 1.3xmedian 11.6x
P/B now vs peer median 3.1xmedian 2.4x 15.4xmedian 2.4x 1.7xmedian 1.2x
PEG now vs peer median -3.29median 1.03 1.75median 1.03 0.27median 0.80

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDHRILMNJANL
Revenue $25.11B $4.49B $237.21M
Gross profit $14.69B $2.98B $75.34M
Operating income $5.13B $882.00M $7.29M
Net income $4.00B $825.00M $6.91M
Free cash flow $5.47B $931.00M $45.13M
R&D $1.62B $960.00M –
EPS (diluted) $5.66 $5.39 $4.49
Cash & equivalents $4.35B $1.04B $33.70M
Total debt $26.56B $1.99B $26.49M
Shares (diluted) 707.60M 153.00M 1.22M
Enterprise value $149.83B $38.07B $2.81M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDHRILMNJANL
P/E 41.2x 52.9x 10.4x
P/FCF 30.1x 46.8x 1.3x
P/Operating cash flow 24.8x 39.8x 1.2x
P/S 6.6x 9.7x 0.2x
P/B 3.1x 15.4x 1.7x
P/Tangible book 5.3x 18.0x -13.8x
EV/EBITDA 24.4x 38.5x 4.2x
EV/EBIT 36.4x 50.4x 6.8x
EV/Revenue 7.4x 9.9x 0.2x
EV/FCF 34.2x 47.7x 1.1x
EV/Operating cash flow 28.1x 40.6x 1.1x
PEG (3Y EPS CAGR) -3.29 1.75 0.27

Growth

14 metrics
MetricDHRILMNJANL
Revenue growth (1Y) 4.6% 4.9% 16.0%
Revenue CAGR (3Y) -0.5% -1.0% 2.7%
Gross profit growth (1Y) 2.6% 4.6% 19.3%
Gross profit CAGR (3Y) -0.9% 2.9% 8.3%
Operating income growth (1Y) 16.1% -31.8% 15.5%
Operating income CAGR (3Y) -7.1% 28.3% 22.0%
Net income growth (1Y) 17.3% -34.4% 114.0%
Net income CAGR (3Y) -14.3% 30.0% 43.8%
EPS growth (1Y) 19.2% -32.7% 106.0%
EPS CAGR (3Y) -12.5% 30.1% 39.1%
Operating cash flow growth (1Y) 7.6% -5.1% 151.6%
Operating cash flow CAGR (3Y) -7.6% 38.1% 46.5%
Free cash flow growth (1Y) 12.4% -9.7% 159.9%
Free cash flow CAGR (3Y) -9.0% 105.0% 47.2%

Profitability

14 metrics
MetricDHRILMNJANL
Gross margin 58.5% 66.4% 31.8%
EBITDA margin 30.5% 25.7% 4.9%
Operating margin 20.4% 19.6% 3.1%
Pretax margin 19.0% 22.6% 3.5%
Net margin 15.9% 18.4% 2.3%
FCF margin 21.8% 20.7% 19.0%
Operating cash flow margin 26.4% 24.4% 19.2%
Return on equity 7.6% 29.9% 21.6%
Return on assets 4.5% 12.5% 4.0%
Return on invested capital 5.7% 15.1% 10.2%
Return on capital employed 6.4% 17.5% 17.7%
Asset turnover 0.3x 0.7x 1.4x
Cash conversion (OCF / net income) 1.7x 1.3x 6.6x
Stock comp / revenue 1.2% 5.9% 0.1%

Financial Health

11 metrics
MetricDHRILMNJANL
Debt / assets 28.8% 29.9% 13.8%
Debt / equity 0.5x 0.7x 0.8x
Net debt / EBITDA 2.9x 0.7x -0.6x
Debt / FCF 4.9x 2.1x 0.6x
Liabilities / assets 43.1% 57.3% 82.7%
Equity / assets 56.9% 42.7% 17.3%
Interest coverage 17.6x 8.9x –
Current ratio 1.7x 1.8x 0.8x
Quick ratio 1.0x 1.2x 0.7x
Cash ratio 0.5x 0.7x 0.3x
Altman Z-score 3.74 8.19 1.49

Shareholder Returns

7 metrics
MetricDHRILMNJANL
Dividend yield 0.6% – –
Net buyback yield 1.8% 1.2% –
Shareholder yield 2.4% 1.2% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDHRILMNJANL
Forward P/E 25.7xFY2026 57.9xFY2026 –
EPS, next fiscal year $9.11FY2026 $4.99FY2026 –
EPS growth, next FY +16.8%FY2026 +3.1%FY2026 –
EPS growth, the year after +8.0% +25.7% –
Revenue, next fiscal year $27.01BFY2026 $4.52BFY2026 –
Revenue growth, next FY +9.9%FY2026 +4.1%FY2026 –
Revenue growth, the year after -1.9% +12.0% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDHRILMNJANL
Held by institutions 81.9% 100.0% –
Institutions holding 2,117 933 –
Change in shares held, QoQ +1.1% +0.0% –
Institutions buying 839 463 –
Institutions selling 1,015 330 –
Buyers to sellers 0.83 1.40 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DHRILMNJANL
DHR 1.00 0.33 -0.04
ILMN 0.33 1.00 0.02
JANL -0.04 0.02 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DHR, ILMN and JANL?

Danaher (DHR) is the largest by market capitalisation: Danaher (DHR) $166.02B, Illumina (ILMN) $43.30B, Janel (JANL) $56.94M.

Which stock is cheaper, DHR, ILMN and JANL?

Janel (JANL) trades on the lowest price-to-earnings ratio (Danaher (DHR) 41.5x, Illumina (ILMN) 52.5x, Janel (JANL) 10.4x). On next year's consensus earnings, Danaher (DHR) is cheapest (Danaher (DHR) 25.7x, Illumina (ILMN) 57.9x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Janel (JANL) grew revenue fastest over the trailing twelve months: Danaher (DHR) +4.6%, Illumina (ILMN) +4.9%, Janel (JANL) +16.0%.

Which company is more profitable?

Illumina (ILMN) has the highest net margin (Danaher (DHR) 15.9%, Illumina (ILMN) 18.4%, Janel (JANL) 2.3%). On return on invested capital, Illumina (ILMN) leads (Danaher (DHR) 5.7%, Illumina (ILMN) 15.1%, Janel (JANL) 10.2%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Danaher (DHR) +7.9%, Illumina (ILMN) +195.3%, Janel (JANL) +33.3%. Over five years, Janel (JANL) compounded fastest (Danaher (DHR) -5.6%/yr, Illumina (ILMN) -6.5%/yr, Janel (JANL) +16.9%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Danaher (DHR) 30.6%, Illumina (ILMN) 50.4%, Janel (JANL) 77.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, DHR, ILMN and JANL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Janel (JANL) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.